Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Glioblastoma is the most common primary central nervous system malignancy and has a poor prognosis. Standard first-line treatment, which includes surgery followed by adjuvant radio-chemotherapy, produces only modest benefits to survival1,2. Here, to explore the feasibility, safety and immunobiologic...
相似书籍
-
Feasibility and safety of targeted axillary dissection guided by intraoperative ultrasound after neoadjuvant treatment
由: Siso, C. (Christian), et al.
出版: (2024) -
Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma
由: Vilalta, A. (Anna), et al.
出版: (2023) -
Characterization of cellular and molecular responses of human glioblastoma to Transforming Growth Factor-β signalling pathway inhibition
由: Gallo, G.O. (Gabriel Osvaldo), et al.
出版: (2016) -
Gliosarcoma /
由: Encalada G., Verónica -
Gliosarcoma /
由: Encalada G., Verónica